Response Genetics Inc (RGDXQ) Financial Statements (2023 and Earlier)

Company Profile

Business Address 1640 MARENGO ST.,
LOS ANGELES,, CA 90033
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,2228,1499,041
Cash and cash equivalents2,2228,1499,041
Receivables7,8106,2265,373
Prepaid expense and other current assets576
Other undisclosed current assets1,183982 
Total current assets:11,21615,35614,991
Noncurrent Assets
Property, plant and equipment1,4061,9351,023
Intangible assets, net (including goodwill)631767575
Intangible assets, net (excluding goodwill)631767575
Other noncurrent assets192 
Total noncurrent assets:2,2292,7021,599
TOTAL ASSETS:13,44518,05816,589
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,9794,2122,917
Accounts payable1,6101,6941,191
Accrued liabilities672667344
Employee-related liabilities1,5481,8511,382
Interest and dividends payable150  
Debt1011571,159
Deferred revenue and credits  483
Other undisclosed current liabilities9681,294713
Total current liabilities:5,0485,6635,272
Noncurrent Liabilities
Long-term debt and lease obligation9,5671,13684
Long-term debt, excluding current maturities9,4641,000 
Capital lease obligations10313684
Total noncurrent liabilities:9,5671,13684
Total liabilities:14,6156,7995,356
Temporary equity, carrying amount 5,50011,776
Stockholders' equity
Stockholders' equity attributable to parent, including:(1,170)5,759(542)
Common stock388337232
Additional paid in capital77,69870,98656,766
Accumulated other comprehensive loss(260)(267)(264)
Accumulated deficit(78,997)(65,297)(57,277)
Warrants and rights outstanding681  
Other undisclosed stockholders' equity attributable to parent(681)  
Total stockholders' equity:(1,170)5,759(542)
TOTAL LIABILITIES AND EQUITY:13,44518,05816,589

Income Statement (P&L) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
16,72019,80118,737
Cost of revenue(438)(10,456)(10,416)
Cost of goods and services sold(10,011)(10,456) 
Other undisclosed gross profit(9,574)  
Gross profit:6,7099,3458,321
Operating expenses(19,716)(17,291)(17,800)
Other undisclosed operating income  1,822
Operating loss:(13,008)(7,946)(7,657)
Nonoperating income (expense)(27)17(14)
Other nonoperating expense  (14)
Interest and debt expense(665)(92)(86)
Loss from continuing operations before equity method investments, income taxes:(13,699)(8,021)(7,757)
Other undisclosed income from continuing operations before income taxes 0 
Net loss available to common stockholders, diluted:(13,699)(8,021)(7,757)

Comprehensive Income ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Net loss:(13,699)(8,021)(7,757)
Comprehensive loss:(13,699)(8,021)(7,757)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent7(3)3
Comprehensive loss, net of tax, attributable to parent:(13,692)(8,024)(7,754)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: